by Gemma Escarré,
Multinational company Grifols, member of CataloniaBio & HealthTech, makes inroads in its research efforts to find a treatment for Alzheimer's disease. The patients enrolled in the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial have finished treatment. Thus ends the experimental phase of the trial, giving way to data collection and evaluation and analysis of the results, which the company plans to announce in the fourth quarter of 2018.
AMBAR is an international and multi-center clinical trial that included 496 patients with mild to moderate Alzheimer's disease across 41 hospitals (20 in Spain and 21 in the United States). Among the participating centers of reference is the Barcelona Alzheimer Treatment and Research Centre (ACE). The center is directed by Dr. Mercè Boada, who collaborated in the design of the clinical trial. AMBAR aims to evaluate whether the progression of Alzheimer's can be stabilized through plasma exchange, a process that entails periodically extracting plasma and replacing it with albumin solution.